Clearing Minimal Residual Disease with Rituximab Consolidation Therapy
- 1 February 2004
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 33-37
- https://doi.org/10.1053/j.seminoncol.2003.12.008
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaBlood, 2002
- In vivodepletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphomaBritish Journal of Haematology, 2000
- Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular LymphomaBlood, 1999
- Should we purge?Bone Marrow Transplantation, 1998
- Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34 + Selection SystemsThe International Journal of Cell Cloning, 1997
- A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's LymphomaBlood, 1997
- High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatmentBlood, 1991
- Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresisBlood, 1991
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984